Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BladderChek Test

This article was originally published in The Tan Sheet

Executive Summary

Diagnostic products developers Matritech and Inverness Medical Innovations have signed a manufacturing and distribution agreement to collaborate and seek FDA approval for OTC sale of the NMP22 BladderChek Test, the companies announce Nov. 6. The product, developed by Matritech, is the only FDA approved physician-office test for both the diagnosis and monitoring of bladder cancer, the companies say. The firms will assess market opportunity under their agreement and "anticipate the OTC distribution would be introduced in the U.S. as soon as FDA approval is received." Home diagnostic products already marketed by Inverness include the Clearblue and Fact Plus home pregnancy tests...

You may also be interested in...



Sun’s Indian Nilotinib Plans Blocked By Novartis

Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.

Centus Gets European Bevacizumab Approval

Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.

IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process

The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel